Anzeigenschluss: 19.09.2024
Erscheinungstermin: 16.10.2024
Schwerpunkt Prostatakarzinom
K. Miller
Einführung ins Thema
Th. Steuber
Oligometastasiertes Prostatakarzinom – lokale und systemische Therapieoptionen
C. Ohlmann
Hormonsensitives metastasiertes Prostatakarzinom – große Fortschritte
A. Omlin
Kastrationsresistentes Prostatakarzinom – alte und neue Therapiemöglichkeiten
Journal Club
Frühes Mammakarzinom
O. Gentilini et al.
Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes. The SOUND randomized clinical trial
NSCLC
M. Tachihara et al.
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer
Lungenkrebs
S. Michels et al.
Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial
Zervixkarzinom
A. Oaknin et al.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Neues aus der Forschung
Lymphom
C. Nielsen et al.
Tattoos as a risk factor for malignant lymphoma: a population-based case-control study
AML
M. Stelljes et al.
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Allgemeine Onkologie
B. T. Li et al.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
HPV-Impfung
R. Adcock et al.
Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination
CME Fortbildung
J. Hecker
CHIP (Klonale Hämatopoese von unbest. Potential)
Onkologie aktuell
Hämatologie und Onkologie
Kongressbericht: Heidelberger Myelomtage
*Die Redaktion behält sich aktuelle Änderungen vor.